CClinicalTrials.gg
CompletedNCT06790732Updated Jan 24, 2025

Preoperative Ultrasound-Guided Peri- Capsular Nerve Group Block on Postoperative Analgesia After Shoulder Arthroscopic Surgery

An interventional study of Saline and Bupivacaine + Dexamethasone in Preoperative, Ultrasound-Guided and PeriCapsular Nerve Group Block, sponsored by Tanta University. Completed at 1 site in Egypt. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-01-24.

Sponsored by Tanta University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled May 2023, registered Jan 2025).
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Study summary

This study aimed to evaluate the analgesic efficacy of preoperative ultrasound-guided peri-capsular nerve group block (PENG) on postoperative analgesia after shoulder arthroscopic surgery.

Read the detailed description

Postoperative pain control after shoulder surgery is challenging, and poor pain management is invariably reflected in poor outcomes, with longer hospitalization and recovery time. The difficulty in reducing pain due to the complexity of shoulder innervation leads to conducting studies to explore selective axillary nerve blocks with a posterior approach or from the axillae.

The peri-capsular nerve group (PENG) block is a regional anesthetic technique. It can be effectively and safely applied under ultrasound guidance in shoulder surgery cases for postoperative analgesia. It targets only the sensory branches and not the posterior mechanoreceptors; there is a potential motor-sparing effect which is desirable for better physical therapy, and earlier discharge.

02

Conditions studied

  • Preoperative
  • Ultrasound-Guided
  • PeriCapsular Nerve Group Block
  • Postoperative Analgesia
  • Shoulder Arthroscopic Surgery

Browse trials for

03

In context

Agnosia

1,190 studies on the registry are indexed under Agnosia; 507 are open to participants now.

This study's enrollment of 60 is below the median of 77 across 1,023 interventional studies indexed under Agnosia.

Browse Agnosia studies →

Lead sponsor

Tanta University is the lead sponsor of 963 studies on the registry; 304 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age from 21 to 65 years.
  • Both sexes.
  • American Society of Anesthesiologists (ASA) physical status I-III.
  • Scheduled for unilateral shoulder arthroscopic surgery.

Exclusion criteria

Exclusion Criteria:

  • Patient refusal.
  • Known hypersensitivity to local anesthetics.
  • Body mass index> 35 kg /m2.
  • Uncooperative or psychiatric patients.
  • Infection at the injection site.
  • Coagulation disorder.
  • Major cardiac, renal, or hepatic diseases.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Sham comparator
    Control Group

    Patients received sham PENG block (just 1mL saline).

    Drug: Saline

  • Experimental
    PeriCapsular Nerve Group Block (PENG) Group

    Patients received real PENG block (15 mL of bupivacaine 0.25% +0.2mg/mL dexamethasone).

    Drug: Bupivacaine + Dexamethasone

Interventions

  • DrugSaline

    Patients received sham PENG block (just 1mL saline).

  • DrugBupivacaine + Dexamethasone

    Patients received real PENG block (15 mL of bupivacaine 0.25% +0.2mg/mL dexamethasone).

    Also known as: PeriCapsular Nerve Group Block (PENG)

06

What researchers measure

Primary outcomes

  1. Time to the first request of rescue analgesia

    Time to the first request of rescue analgesia was recorded from the end of the surgery till first dose of morphine administrated.

    Time frame: 24 hours postoperatively

Secondary outcomes

  1. Degree of pain

    The degree of pain was assessed using the Numerical Rating Scale (NRS) Pain score (metric score from 0 to 10 where 0 = no pain and 10 = maximal pain). NRS was recorded at PACU and 2, 4, 6, 8, 12, 16, 20, and 24 h postoperative.

    Time frame: 24 hours postoperatively

  2. Total morphine consumption

    If patient numeric rating score was more than 3, patients received 3 mg morphine slowly intravenously. Morphine injection was repeated whenever required.

    Time frame: 24 hours postoperatively

07

Study locations

1 site
  • Tanta University
    Tanta, El-Gharbia 31527, Egypt
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06790732
Lead sponsor
Tanta University
Responsible party
Kareem Ayman Khattab (Resident of Anesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt., Tanta University) — Principal investigator
First posted
Jan 24, 2025
Start date
May 1, 2023
Primary completion
May 1, 2024
Completion
May 1, 2024
Last update
Jan 24, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion